The Use of Glucocorticoid in the Management of Adverse Effects Related to Immunocheckpoint Inhibitors / 中国肺癌杂志
Chinese Journal of Lung Cancer
;
(12): 615-620, 2019.
Artículo
en Chino
| WPRIM
| ID: wpr-775583
ABSTRACT
Immunocheckpoint inhibitors (ICIs) activated the patients' tumor immunity to kill the tumor cell, and brought new hope to patients with tumor. However, a series of immunocheckpoint inhibitors related adverse effects (irAEs) may also occur based on immune injury. Glucocorticoids are the basis for the treatment of such irAEs. However, the usage, dosage and course of treatment of glucocorticoid in irAEs are different from those in classic autoimmune diseases. Meanwhile, long-term use of large doses of glucocorticoids may cause serious adverse effects too. In this paper, the mechanism, dosage forms, adverse effects and management of glucocorticoids are described in detail, providing references and suggestions for oncologists to apply glucocorticoids in clinical practice.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Chino
Revista:
Chinese Journal of Lung Cancer
Año:
2019
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS